Patents Examined by Stephen L. Rawlings
  • Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
    Patent number: 10596243
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: March 24, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
    Patent number: 10597449
    Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: March 24, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Vittoria Zinzalla, Klaus-Peter Kuenkele, Marie-Ange Buyse, Karen Cromie, Stephanie Staelens, Beatrijs Strubbe
  • Humanized monoclonal antibodies and methods of use
    Patent number: 10584172
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: March 10, 2020
    Assignees: DANA FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
  • Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
    Patent number: 10576135
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: March 3, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Jens Fritsche, Harpreet Singh, Andrea Mahr, Martina Ott, Claudia Wagner, Oliver Schoor
  • Human antigen binding proteins that bind ?-Klotho, FGF receptors and complexes thereof
    Patent number: 10570205
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: February 25, 2020
    Assignee: Amgen, Inc.
    Inventors: Shaw-Fen Sylvia Hu, Ian Nevin Foltz, Chadwick Terence King, Yang Li, Taruna Arora
  • Cell mediated immune response assay
    Patent number: 10564150
    Abstract: This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches diagnosis of a subject's exposure to an antigen based on cell-mediated immunoresponsiveness with enhanced sensitivity which is achieved by adding a non-reducing sugar during incubation of the sample with the antigen.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: February 18, 2020
    Assignee: Cellestis Limited
    Inventors: Jeff Boyle, Ashley Knights, Carmen Munian
  • Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
    Patent number: 10561718
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: February 18, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Jens Fritsche, Harpreet Singh, Andrea Mahr, Martina Ott, Claudia Wagner, Oliver Schoor
  • Lung cancer differential marker
    Patent number: 10539576
    Abstract: An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: January 21, 2020
    Assignees: National Institute of Advanced Industrial Science and Technology, Tokyo Medical University
    Inventors: Hisashi Narimatsu, Akira Togayachi, Yuzuru Ikehara, Hiroyuki Kaji, Atsushi Kuno, Takashi Ohkura, Hideki Matsuzaki, Yoshitoshi Hirao, Jun Iwaki, Minako Abe, Masaharu Nomura, Masayuki Noguchi
  • Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
    Patent number: 10525084
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: January 7, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Covalently linked polypeptide toxin-antibody conjugates
    Patent number: 10519249
    Abstract: Herein is reported a conjugate of a haptenylated polypeptide toxin and an anti-hapten antibody, wherein a disulfide bond is formed between a cysteine residue either before or after the lysine residue that is used for hapten-conjugation and a cysteine residue in the CDR2 of the antibody, whereby the CDR2 is determined according to Kabat.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: December 31, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Eike Hoffmann, Stefan Dengl, Klaus Mayer
  • Compositions and methods for treatment of cancer
    Patent number: 10508143
    Abstract: Compositions, e.g., compositions comprising cellular therapeutics and/or protein therapeutics, and methods of using such compositions for treating cancer are described.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: December 17, 2019
    Assignee: Aleta Biotherapeutics Inc.
    Inventors: Roy Lobb, Paul Rennert
  • Anti-ERBB3 antibodies
    Patent number: 10494441
    Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: December 3, 2019
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
  • Human monoclonal antibodies specific for CD22
    Patent number: 10494435
    Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: December 3, 2019
    Assignee: The Government of the United States America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
  • Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
    Patent number: 10485859
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: November 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
    Patent number: 10449239
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: October 22, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Jens Fritsche, Harpreet Singh, Andrea Mahr, Martina Ott, Claudia Wagner, Oliver Schoor
  • Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
    Patent number: 10434155
    Abstract: The invention provides a peptide derived from the interleukin-13 receptor ?2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: October 8, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Hideho Okada, Walter J. Storkus
  • Modulation of stimulatory and non-stimulatory myeloid cells
    Patent number: 10428143
    Abstract: Provided herein are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an antigen binding protein such as an antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: October 1, 2019
    Assignee: The Regents of the University of California
    Inventors: Matthew Krummel, Miranda Broz, Denise Wolf, Joshua Pollack, Mikhail Biennewies
  • Prostate-specific membrane antigen (PSMA) targeting peptides
    Patent number: 10421783
    Abstract: Described herein is the discovery of novel PSMA-specific peptides, which were identified through a novel combinatorial biopanning method. One of the novel PSMA-specific peptides discovered, GTIQPYPFSWGY (or GTI) (SEQ ID NO: 2), exhibits high binding affinity and selectivity to PSMA and PSMA-positive prostate cancer cells. It was found that GTI can mediate internalization of the apoptotic KLA peptide (SEQ ID NO: 10) to PSMA-positive LNCaP cells and induce cell death. Moreover, a FAM-labeled GTI peptide shows a high and specific tumor uptake in nude mice bearing human prostate cancer xenografts. It was demonstrated that the GTI peptide can be employed as a PSMA-specific ligand for prostate cancer diagnosis and/or for targeted drug delivery to prostate cancer cells.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: September 24, 2019
    Assignee: The Curators of the University of Missouri
    Inventors: Kun Cheng, Wei Jin
  • Variants of IgG Fc with limited amine groups
    Patent number: 10421796
    Abstract: Lysine-depleted variants of fragment crystallizable (Fc) regions of immunoglobulins are disclosed. Also disclosed are fusion proteins comprised of N-terminal targeting or active peptide domains fused with such lysine-depleted variant IgG-Fc domains. Polynucleotides encoding such proteins, compositions and kits containing such proteins, and methods of using such proteins are also disclosed.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: September 24, 2019
    Inventor: Gray D Shaw
  • Biological products
    Patent number: 10407513
    Abstract: A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab? fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab? fragment and one or more single domain antibodies which may be stabilized by a disulfide bond therebetween.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: September 10, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Ralph Adams, Laura Hancock, Sam Philip Heywood